Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

Advancements in therapeutic modalities are necessitating change in drug delivery to help negate some of the expense of development and manufacturing.

Influencing Change in Drug Delivery

Bianca Piachaud-Moustakis is lead writer at Pharmavision, Pharmavision.co.uk.

EnteroBiotix is harnessing the power of the microbiome to target an array of diseases.

Frontrunner in Microbiome Therapeutics

Lilly will cap insulin prices for patients with and without insurance at $35 per month.

Eli Lilly to Cap Out-Of-Pocket Insulin Costs at $35

Quotient Sciences’ facility expansion is designed to increase support for fully integrated drug development programs.

Quotient Sciences Expands Formulation Development Capabilities at Nottingham Facility

is an executive director at WuXi Biologics.

Wesley Wang is vice-president at WuXi Biologics.

Weichang Zhou is president at WuXi Biologics.

In this paper, the authors lay out some commonly accepted HCP analytical methods, the challenges of HCP assay, and provide recommendations on what can easily be accomplished in-house and when it may be better to outsource.

Current Trends in Host Cell Protein Detection for Biologics Manufacturing

Shifting toward more technological solutions and ensuring a greater understanding of the workforce’s needs will give both CROs and sponsors a market advantage.

CROs Gaining a Competitive Edge

Suzanne Shelley is contibuting editor to 

Efforts to optimize the delivery of sensitive biotherapeutics continue to evolve.

Safeguarding Biologics—Blending Engineering Ingenuity and Managerial Excellence

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

This new pioneering phase of mRNA is loaded with potential, but also obstacles and false dawns. 

The Commercial Message mRNA Products Send

Hallie Forcinio is packing editor for Pharmaceutical Technology and Pharmaceutical Technology Europe, editorhal@sbcglobal.net.

Materials enhance sustainability and efficiency. 

New Blister Packaging Options

Bio/pharma has evolved and adapted to a variety of challenges in 2022, but what might be on the cards for the industry in 2023?